Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer

FRIDAY, April 22, 2022 (HealthDay News) -- The addition of tislelizumab to chemotherapy improves progression-free survival (PFS) in recurrent/metastatic nasopharyngeal cancer (RM NPC), according to a study presented April 18 as part of the American Society for Clinical Oncology Plenary Series.
Li Zhang, M.D., from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues reported an updated analysis of PFS, PFS after next line of treatment (PFS2), and overall survival (OS) among 263 patients with RM NPC who were randomly assigned to receive tislelizumab + chemotherapy versus placebo + chemotherapy in a 1:1 ratio.
The researchers found that independent review committee-assessed PFS was consistent with the interim data analysis at an updated data cutoff (Sept. 30, 2021), showing significant improvement for tislelizumab + chemotherapy versus placebo + chemotherapy (median PFS, 9.6 versus 7.4 months; hazard ratio, 0.50; 95 percent confidence interval, 0.37 to 0.68). In the tislelizumab + chemotherapy arm, median PFS2 and OS were not reached, and they were 13.9 and 23.0 months, respectively, in the placebo + chemotherapy arm (PFS2: hazard ratio, 0.38; 95 percent confidence interval, 0.25 to 0.58; OS: hazard ratio, 0.60; 95 percent confidence interval, 0.35 to 1.01).
"These findings support the use of tislelizumab in combination with chemotherapy as a potential standard-of-care as first line therapy in recurrent or metastatic nasopharyngeal cancer," Zhang said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including BeiGene, which manufactures tislelizumab and funded the study.
Related Posts
Can a Computer Program Help Docs Spot Breast Cancer?
FRIDAY, Sept. 24, 2021 (HealthDay News) -- An artificial intelligence tool could...
200 Million Americans Are Now Fully Vaccinated as COVID Cases Spike
THURSDAY, Dec. 9, 2021 (HealthDay News) -- The United States reached a vaccine...
Many With Psychosis Have Long-Term Functional Morbidity
MONDAY, Nov. 21, 2022 (HealthDay News) -- A diagnosis of psychosis in...
Social Vulnerability Tied to Higher Assault-Related Firearm Death Rates for Youth
FRIDAY, May 26, 2023 (HealthDay News) -- States with restrictive gun laws have...
